参考文献：

[1]Siegel R L, Kratzer T B, Giaquinto A N, et al. Cancer statistics, 2025[J]. CA: A cancer journal for Clinicians, 2025, 75(1): 10～45.

[2]Frost J A, Webster K E, Bryant A, et al. Lymphadenectomy for the management of endometrial cancer[J]. The Cochrane Database of Systematic Reviews, 2017, 10(10): CD007585.

[3]中国研究型医院学会妇产科专业委员会. 子宫内膜癌前哨淋巴结切除临床应用专家共识[J]. 中国妇产科临床杂志, 2020, 21(4): 438～440.

[4]Abu-Rustum N R, Campos S M, Amarnath S, et al. NCCN guidelines® insights: uterine neoplasms, version 3.2025[J]. Journal of the National Comprehensive Cancer Network: JNCCN, 2025, 23(8): 284～291.

[5]Park K U, Somerfield M R, Anne N, et al. Sentinel lymph node biopsy in early-stage breast cancer: asco guideline update[J]. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2025, 43(14): 1720～1741.

[6]Amaral T, Ottaviano M, Arance A, et al. Cutaneous melanoma: esmo clinical practice guideline for diagnosis, treatment and follow-up[J]. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 2025, 36(1): 10～30.

[7]Della Corte L, Giampaolino P, Mercorio A, et al. Sentinel lymph node biopsy in endometrial cancer: state of the art[J]. Translational Cancer Research, 2020, 9(12): 7725～7733.

[8]Zhai L, Zhang X, Cui M, et al. Sentinel lymph node mapping in endometrial cancer: a comprehensive review[J]. Frontiers in Oncology, 2021, 11.

[9]Cristóbal Quevedo I, Cristóbal García I, Gracia M, et al. Personalized sentinel node mapping in endometrial cancer by the indocyanine green implementation as single tracer: a case control study[J]. Journal of Personalized Medicine, 2023, 13(2): 170.

[10]Liang S, Wang Z, Chen J, et al. Carbon nanoparticles combined with indocyanine green for sentinel lymph node detection in endometrial carcinoma[J]. Journal of Surgical Oncology, 2021, 124(3): 411～419.

[11]Rossi E C, Kowalski L D, Scalici J, et al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (fires trial): a multicentre, prospective, cohort study[J]. The Lancet Oncology, 2017, 18(3): 384～392.

[12]Concin N, Matias-Guiu X, Cibula D, et al. ESGO–estro–esp guidelines for the management of patients with endometrial carcinoma: update 2025[J]. The Lancet Oncology, 2025, 26(8): e423～e435.

[13]McCluggage W G, Bosse T, Gilks C B, et al. FIGO 2023 endometrial cancer staging: too much, too soon?[J]. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society, 2024, 34(1): 138～143.

[14]Concin N, Matias-Guiu X, Cibula D, et al. ESGO-estro-esp guidelines for the management of patients with endometrial carcinoma: update 2025[J]. The Lancet. Oncology, 2025, 26(8): e423～e435.

[15]Persson J, Salehi S, Bollino M, et al. Pelvic sentinel lymph node detection in high-risk endometrial cancer (shrec-trial)-the final step towards a paradigm shift in surgical staging[J]. European Journal of Cancer (Oxford, England: 1990), 2019, 116: 77～85.

[16]Cusimano M C, Vicus D, Pulman K, et al. Assessment of sentinel lymph node biopsy vs lymphadenectomy for intermediate- and high-grade endometrial cancer staging[J]. JAMA Surgery, 2021, 156(2): 157～164.

[17]Berek J S, Matias-Guiu X, Creutzberg C, et al. FIGO staging of endometrial cancer: 2023[J]. International Journal of Gynecology & Obstetrics, 2023, 162(2): 383～394.

[18]董阳阳, 赵路阳, 康南, 等. 子宫内膜癌分子分型临床应用中国专家共识(2024年版)[J]. 中国实用妇科与产科杂志, 2024, 40(6): 638～644.

[19]Chacon E, Boria F, Lyer R R, et al. SENECA study: staging endometrial cancer based on molecular classification[J]. International Journal of Gynecological Cancer, 2024, 34(9): 1313～1321.

[20]Dabi Y, Bendifallah S, Kolanska K, et al. Anatomical basis of lymph node detection in gynecologic cancers: a review from a surgical perspective[J]. Chinese Clinical Oncology, 2021, 10(2): 15.

[21]Abu-Rustum N R, Gomez J D, Alektiar K M, et al. The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes[J]. Gynecologic Oncology, 2009, 115(2): 236～238.

[22]Han L, Chen Y, Zheng A, et al. Paraaortic lymph node metastasis in endometrial cancer patients: a comprehensive analysis of rates, survival outcomes, and risk factors through systematic review and meta-analysis[J]. Frontiers in Oncology, 2024, 14.

[23]Kumar S, Podratz K C, Bakkum-Gamez J N, et al. Prospective assessment of the prevalence of pelvic, paraaortic and high paraaortic lymph node metastasis in endometrial cancer[J]. Gynecologic Oncology, 2014, 132(1): 38～43.

[24]Shi J, Shi Z, Chen Q, et al. The progress and prospect of sentinel lymph node mapping in endometrial carcinoma[J]. Frontiers in Medicine, 2023, 10.

[25]Cosma S, Ferraioli D, Borella F, et al. Link between isolated para-aortic lymph node metastasis and intrauterine cancer site in early stage endometrial cancer[J]. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society, 2024, 34(12): 1881～1887.

[26]Olawaiye A B, Mutch D G. Lymphnode staging update in the american joint committee on cancer 8th edition cancer staging manual[J]. Gynecologic Oncology, 2018, 150(1): 7～8.

[27]Clark C, Loizzi V, Cormio G, et al. Sentinel lymph node assessment in endometrial cancer: a review[J]. Cancers, 2024, 16(18): 3202.

[28]Kim C H, Soslow R A, Park K J, et al. Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging[J]. International journal of gynecological cancer : Official journal of the International Gynecological Cancer Society, 2013, 23(5): 964～970.

[29]Matsuo K, Chen L, Neuman M K, et al. Lymph node isolated tumor cells in patients with endometrial cancer[J]. JAMA Network Open, 2024, 7(3): e240988.

[30]Zhuang Y, Xu Y, Deng P, et al. The prognostic significance and role of adjuvant therapy for low-volume nodal metastasis in apparent early stage endometrial cancer: an updated systematic review and meta-analysis[J]. Journal of Gynecologic Oncology, 2025, 36(5).